- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00556894
Oral CF101 Tablets and Methotrexate Treatment in Rheumatoid Arthritis Patients
February 27, 2018 updated by: Can-Fite BioPharma
A Phase 2, Multicenter, Randomized, Double-Blind, Placebo-Controlled, Dose-Finding Study of the Safety and Efficacy of Daily CF101 Administered Orally, When Added to Weekly Methotrexate, in Patients With Active Rheumatoid Arthritis
This trial will test the hypothesis that the addition of CF101, a novel anti-inflammatory agent, will improve the clinical condition of patients with rheumatoid arthritis who still have active joint inflammation despite taking methotrexate for at least 6 months.
Study Overview
Detailed Description
This will be a multi-center, randomized, double-blind, parallel-group, placebo-controlled, dose-finding study in which patients with active RA despite receiving methotrexate for at least 6 months (at unchanged doses for >=2 months) will be randomized to the addition of either CF101 0.1 mg, CF101 1 mg, or placebo given orally q12h for 12 weeks.
Screening examinations will occur within 1 month prior to dosing.
Washout of other disease-modifying antirheumatic drugs (DMARDs) (with the exception of hydroxychloroquine), including biological agents, will occur prior to dosing; if washout is necessary, patients must re-qualify for inclusion following the washout.
Doses of nonsteroidal anti-inflammatory drugs (NSAIDS) and corticosteroids must be stable for >=1 month prior to dosing and remain so during protocol participation.
Disease activity will be assessed using swollen and tender joint counts, physician and patient global assessments (by visual analog scale, VAS), patient reported pain (by VAS), a Health Assessment Questionnaire (HAQ) Disability Index (DI), Westergren erythrocyte sedimentation rate (ESR, Screening, Weeks 0 and12), and C-reactive protein (CRP) levels.
Assessments will take place at Screening, Baseline (Week 0), and at Weeks 2, 4, 8, and 12.
Study Type
Interventional
Enrollment (Actual)
253
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Plovdiv, Bulgaria, 4002
- Clinic of Rheumatology at MHAT 'Sveti Georgi'
-
Sofia, Bulgaria, 1612
- Clinic of Rheumatology at MHAT 'Sveti Ivan Rilski'
-
Sofia, Bulgaria
- Clinic of internal diseases at NMTH 'Tzar Boris Treti'
-
Stara Zagora, Bulgaria, 6000
- Second Clinic of Internal Diseases at MHAT 'Stara Zagora'
-
Varna, Bulgaria, 9010
- Clinic of Rheumatology at MHAT 'Sveta Marina' - Varna
-
-
-
-
-
Hradec Kralove, Czechia, 50005
- University Hospital Hradec Kralove
-
Prague, Czechia, 12850
- Institute of Rheumatology
-
Zlin, Czechia, 76001
- Rheumotology Out-patient Clinic
-
-
-
-
-
Afula, Israel
- Haemek Medical Center
-
Ashkelon, Israel, 78278
- Barzilai Medical Center
-
Haifa, Israel, 31096
- Rambam Medical Center
-
Jerusalem, Israel
- Hadassah Har-Hazofim Medical Center
-
Kfar-Saba, Israel, 44281
- Meir Medical Center
-
-
-
-
-
Elblag, Poland, 82300
- Wojewódzki Szpital Zespolony w Elblągu
-
Lublin, Poland, 20607
- Niepubliczny Zaklad Opieki Zdrowotnej
-
Sopot, Poland, 81967
- Wojewodzki Zespol Reumatologiczny w Sopocie
-
Szczecin, Poland, 71252
- Samodzielny Publiczny Szpital Kliniczny Nr 1 P.A.M. w Szczecinie
-
Torun, Poland, 87100
- Niepubliczny Zaklad Opieki Zdrowotnej "NASZ LEKARZ"
-
-
-
-
-
Belgrade, Serbia, 11000
- Institute of Rheumatology - Belgrade
-
Niska Banja, Serbia, 18205
- Institute for Prevention, Treatment, and Rehabilitation of Rheumatoid and Cardiovascular Diseases Niska Banja
-
-
-
-
-
Donetsk, Ukraine, 83114
- Central Municipal Clinical Hospital nº1
-
Kiev, Ukraine, 01023
- Kyiv Central Municipal Hospital
-
Kiev, Ukraine, 01103
- City Clinical Hospital N12
-
Kiev, Ukraine, 03680
- National Scientific Centre of AMS of Ukraine
-
Kiev, Ukraine, 04053
- O.O. Bogomolets National Medical University
-
Vinnycia, Ukraine, 21018
- Vinnitsya Regional Clinical Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Males and females ages 18-75 years
- Meet the criteria of the American College of Rheumatology for RA (Arnett FC et al. Arthritis Rheum 1988;31:315-324; refer to Appendix 1. diagnostic criteria for Rheumatoid Arthritis)
- Not bed- or wheelchair-bound
- Active RA, as indicated by the presence of (a) >=6 swollen joints (28 joint count); AND (b) >=6 tender joints (28 joint count); AND either: (c) Westergren ESR of >=28 mm/hour; OR (d) CRP level above the upper limit of normal for the central reference laboratory
- Treatment with weekly oral or parenteral methotrexate for >=6 months prior to baseline
- Methotrexate route of administration has been unchanged for >=2 months prior to baseline
- Dose of methotrexate has been stable at 15-25 mg/week for >=2 months, and is expected to remain stable throughout the study; the stable dose of methotrexate may alternatively be 10-12.5 mg/week if documented toxicity has precluded a higher dose
- If taking hydroxychloroquine or chloroquine, administration duration has been for >=3 months and dose has been stable for >=2 months prior to baseline
- If taking a nonsteroidal anti-inflammatory agent (NSAID), dose has been stable for at least 1 month prior to baseline, and will remain unchanged during protocol participation
- If taking an oral corticosteroid, dose is <10 mg/day prednisone or equivalent, has been stable for at least 1 month prior to the stabilization period, and will remain stable through the stabilization and entire treatment and follow-up period
- Negative screening serum pregnancy test for female patients of childbearing potential
- Females of childbearing potential must utilize, throughout the course of the trial, 2 methods of contraception deemed adequate by the Investigator (for example, oral contraceptive pills plus a barrier method)
Exclusion Criteria:
- Receipt of any of the following for at least a 1 month stabilization period prior to dosing: sulfasalazine, oral or injectable gold, azathioprine, minocycline, penicillamine, anakinra
- Receipt of etanercept for at least a 6 week period prior to dosing
- Receipt of cyclosporine, infliximab or adalimumab for at least a 2 month period prior to dosing
- Receipt of leflunomide for at least a 2 month period prior to screening, unless patient has undergone cholestyramine washout at least 1 month prior to dosing
- Receipt of cyclophosphamide for at least a 6 month period prior to dosing
- Receipt of rituximab at any previous time
- Participation in a previous trial CF101 trial
- Use of oral corticosteroids >10 mg of prednisone, or equivalent, per day
- Change in NSAID dose level for 1 month prior to dosing
- Change in oral corticosteroid dose level during the 1 month prior to, or during, the stabilization period vChange in hydroxychloroquine or chloroquine dose level during the 2 months prior to, or during, the stabilization period
- Receipt of parenteral or intra-articular corticosteroids during the 1 month prior to, or during, the stabilization period
- Significant cardiac arrhythmia or conduction block, congestive heart failure, or any other evidence of clinically significant heart disease; other clinically significant findings on screening electrocardiogram (ECG)
- Hemoglobin level <9.0 gm/dL at the screening visit
- Platelet count <125,000/mm3 at the screening visit
- White blood cell count <3000/mm3 at the screening visit
- Serum creatinine level outside the central laboratory's normal limits at the screening visit
- Liver aminotransferase (ALT and/or AST) levels greater than 1.25 times the central laboratory's upper limit of normal at the screening visit
- Significant acute or chronic medical or psychiatric illness that, in the judgment of the Investigator, could compromise patient safety, limit the patient's ability to complete the study, and/or compromise the objectives of the study
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: CF101 0.1 mg
CF101 0.1 mg was given orally q12h
|
orally q12h
Other Names:
|
Experimental: CF101 1 mg
CF101 1 mg was given orally q12h
|
orally q12h
Other Names:
|
Placebo Comparator: Placebo
Matched placebo was given orally q12h
|
orally q12h
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACR20 at Week 12
Time Frame: 12 weeks
|
Number of patients that achieved 20% response at week 12 in American College of Rheumatology Criteria
|
12 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
ACR 20/50/70, ITT and Evaluable Population, Last Observation Carried Disease Activity Score (DAS28) Change From Baseline at Each Visit in the Efficacy Parameters
Time Frame: 12 weeks
|
ACR20/50/70 responses over time (intent-to-treat [ITT], last observation carried forward [LOCF]), mean changes in individual components of the ACR response criteria, DAS28, European League Against Rheumatism (EULAR) responses
|
12 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
February 1, 2008
Primary Completion (Actual)
March 1, 2009
Study Completion (Actual)
April 1, 2009
Study Registration Dates
First Submitted
November 8, 2007
First Submitted That Met QC Criteria
November 9, 2007
First Posted (Estimate)
November 12, 2007
Study Record Updates
Last Update Posted (Actual)
March 29, 2018
Last Update Submitted That Met QC Criteria
February 27, 2018
Last Verified
August 1, 2011
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CF101-203RA
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Rheumatoid Arthritis
-
Janssen Research & Development, LLCWithdrawnActive Rheumatoid Arthritis; Rheumatoid Arthritis
-
Centocor, Inc.CompletedRheumatoid Arthritis, Juvenile
-
AmgenTerminated
-
Children's Hospital Medical Center, CincinnatiNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedJuvenile Rheumatoid ArthritisUnited States
-
AmgenImmunex CorporationCompletedJuvenile Rheumatoid Arthritis
-
National Institute of Arthritis and Musculoskeletal...Children's Hospital Medical Center, CincinnatiCompleted
-
University of PittsburghNational Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)CompletedRheumatoid Arthritis | Juvenile Rheumatoid ArthritisUnited States
-
University of Missouri-ColumbiaCompletedJuvenile Rheumatoid ArthritisUnited States
-
Assistance Publique - Hôpitaux de ParisSociete Francaise de RhumatologieRecruiting
-
Amsterdam UMC, location VUmcEuropean CommissionCompletedRheumatoId ArthritisNetherlands, Germany, Portugal, Italy, Hungary, Romania, Slovakia
Clinical Trials on CF101
-
Can-Fite BioPharmaCompleted
-
Can-Fite BioPharmaRabin Medical CenterCompleted
-
Can-Fite BioPharmaWithdrawnOsteoarthritis of the KneeIsrael
-
Can-Fite BioPharmaCompleted
-
Can-Fite BioPharmaCompletedKeratoconjunctivitis SiccaIsrael
-
Can-Fite BioPharmaCompletedOcular Hypertension | GlaucomaIsrael, Bulgaria
-
Can-Fite BioPharmaCompletedPlaque PsoriasisIsrael, United States, Bulgaria, Romania
-
Can-Fite BioPharmaWithdrawnUveitis, Posterior | Uveitis, IntermediateIsrael
-
Can-Fite BioPharmaTerminatedRheumatoid ArthritisBosnia and Herzegovina, Canada, Israel, Moldova, Republic of, Poland, Romania, Serbia
-
Can-Fite BioPharmaCompletedRheumatoid ArthritisUnited States, Bulgaria, Israel, Poland, Romania, Serbia, Ukraine